Latest Technology Platforms News

Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.

Weebit Nano has solidified its position in the semiconductor memory sector by signing a major licensing agreement with onsemi and raising A$50 million in capital. The company is well-funded and advancing multiple commercial and technical milestones.

Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Way2VAT has posted a record quarterly revenue of A$1.49 million in Q4 FY24, driving a 43% increase in full-year revenue to A$4.72 million. The fintech continues to expand its enterprise client base and implement cost reductions to support future growth.

BlueBet Holdings has delivered positive EBITDA for the first half of FY25 ahead of schedule, driven by strategic customer reactivation and enhanced platform efficiencies following its merger with betr.

Wisr has reported a robust Q2FY25 with loan originations surging 77% year-on-year to $93.5 million, alongside improving credit metrics and a well-capitalised balance sheet.

Redivium's Q2 FY25 report reveals strategic progress in lithium-ion battery recycling across Europe, including new partnerships and feasibility studies, while navigating tight cash reserves and a critical entitlement offer.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.

Raiz Invest Limited reports robust growth in Q2 FY25 with active customers rising 8.5% year-on-year and funds under management surging 32.4%, underpinned by product innovation and strong net inflows.

Clarity Pharmaceuticals will present compelling data on its 64Cu-SAR-bisPSMA diagnostic agent at two leading oncology conferences, highlighting earlier and more accurate prostate cancer lesion detection than current standards.

IperionX has completed its inaugural end-to-end titanium powder production cycle using its proprietary HAMR process and secured exclusive rights to breakthrough titanium technologies, positioning itself for expanded manufacturing capacity and strong market demand.